Blocking the Ghrelin Receptor: A Potential New Approach to Treating Alcohol Dependence

The authors conducted an updated narrative review of recent preclinical, clinical, and experimental data examining the ghrelin-GHSR-1A signaling pathway in the context of alcohol use disorder. They focused on functional and molecular mechanisms of central ghrelin signaling at different levels of alcohol craving.

Alcohol use disorder affects hundreds of millions of people globally, yet existing treatments have limited effectiveness and high relapse rates. The ghrelin system represents an entirely different therapeutic target — one that addresses the neurological reward mechanisms driving addiction rather than just managing withdrawal symptoms. If GHSR-1A antagonists prove effective in clinical trials, they could offer a fundamentally new approach to addiction medicine.

This research sits at the intersection of peptide biology and addiction neuroscience. The ghrelin system's involvement in reward processing extends beyond alcohol — similar mechanisms have been explored for other substance use disorders and behavioral addictions. Understanding how peptide hormones modulate the brain's reward circuitry could reshape addiction treatment broadly, moving toward precision approaches that target specific neurobiological pathways rather than relying on generalized behavioral interventions.

This is a narrative review that synthesizes existing preclinical and clinical data without conducting new experiments. Most evidence for GHSR-1A antagonism in alcohol dependence comes from animal models, with limited human clinical data available. The complex neuro-psycho-endocrinological nature of alcohol use disorder means that targeting a single receptor pathway may have limited standalone efficacy. Translation from preclinical findings to effective human therapies remains unproven.